Literature DB >> 33280853

A model for the incremental burden of invasive Haemophilus influenzae type b due to a decline of childhood vaccination during the COVID-19 outbreak: A dynamic transmission model in Japan.

Taito Kitano1, Hirosato Aoki2.   

Abstract

BACKGROUND: The current coronavirus disease 2019 (COVID-19) outbreak has caused a persistent decline in childhood vaccination coverage, including Haemophilus influenzae type b (Hib) vaccine, in some countries. Our objective was to evaluate the impact of decreased Hib vaccination due to COVID-19 on invasive Hib disease burden in Japan.
METHODS: Using a deterministic dynamic transmission model (susceptible-carriage-infection-recovery model), the incidence rates of invasive Hib disease in under 5 year olds in rapid vaccination recovery and persistent vaccination declined scenarios were compared for the next 10 years after 2020. The national Hib vaccination rate after the impact of COVID-19 reduced to 87% and 73% in 2020 from approximately 97% each in 2013-2019 for primary and booster doses.
RESULTS: While the persistent decline scenarios revealed an increase in invasive Hib disease incidence to 0.50/100,000 children under 5 years old, the incidence of the rapid recovery scenario slightly increased with a consistent decline of incidence after 2021. The shorter the duration of the decline in vaccination rate was, the smaller the incremental disease burden observed in the model. Compared to the rapid recovery scenario, the permanent decline scenario showed a 296.87 cumulative incremental quality-adjusted life years (QALY) loss for the next 10 years.
CONCLUSIONS: The persistent decline of Hib vaccination rate due to COVID-19 causes an incremental disease burden irrespective of the possible decline of Hib transmission rate by COVID-19 mitigation measures. A rapid recovery of vaccination coverage rate can prevent this possible incremental disease burden.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Coronavirus; Disease burden; Haemophilus influenzae; Impact; Mathematical model; Quality-adjusted life years; SARS-CoV-2; Vaccine preventable diseases

Year:  2020        PMID: 33280853     DOI: 10.1016/j.vaccine.2020.11.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Impact that the COVID-19 pandemic on routine childhood vaccinations and challenges ahead: A narrative review.

Authors:  Elena Chiappini; Sara Parigi; Luisa Galli; Amelia Licari; Ilaria Brambilla; Maria Angela Tosca; Giorgio Ciprandi; Gianluigi Marseglia
Journal:  Acta Paediatr       Date:  2021-06-02       Impact factor: 4.056

Review 2.  Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: A systematic review.

Authors:  SeyedAhmad SeyedAlinaghi; Amirali Karimi; Hengameh Mojdeganlou; Sanam Alilou; Seyed Peyman Mirghaderi; Tayebeh Noori; Ahmadreza Shamsabadi; Omid Dadras; Farzin Vahedi; Parsa Mohammadi; Alireza Shojaei; Sara Mahdiabadi; Nazanin Janfaza; Abolfath Keshavarzpoor Lonbar; Esmaeil Mehraeen; Jean-Marc Sabatier
Journal:  Health Sci Rep       Date:  2022-02-18

3.  The impact of COVID-19 pandemic control on vaccine-preventable invasive bacterial diseases in Piedmont (Italy).

Authors:  Marco Peradotto; A Bondi; D Lombardi; P Bottino; E Zanotto; A M Barbui; R Cavallo
Journal:  Infection       Date:  2022-02-16       Impact factor: 3.553

4.  Estimating the global and regional burden of meningitis in children caused by Haemophilus influenzae type b: A systematic review and meta-analysis.

Authors:  Jay J Park; Sandhya Narayanan; Jakov Tiefenbach; Ivana Lukšić; Boni Maxime Ale; Davies Adeloye; Igor Rudan
Journal:  J Glob Health       Date:  2022-03-05       Impact factor: 4.413

5.  The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19.

Authors:  Taito Kitano; Hirosato Aoki
Journal:  Comput Biol Med       Date:  2021-04-24       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.